US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada, and biotechnology company Moderna Inc (Nasdaq:MRNA) announced on Monday that they have initiated the INTerpath-009 Phase 3 clinical trial evaluating the investigational individualised neoantigen therapy, V940 (mRNA-4157), in combination with KEYTRUDA (pembrolizumab) for early-stage non-small cell lung cancer (NSCLC) patients.
This trial will assess the combination therapy's impact on disease-free survival, overall survival and other key measures in patients who have received neoadjuvant KEYTRUDA and chemotherapy.
A global, randomised, double-blind Phase 3 trial, INTerpath-009 will evaluate 680 patients with resected (R0 or R1) Stage II, IIIA, IIIB (N2) NSCLC who did not achieve a pathological complete response (pCR) after neoadjuvant KEYTRUDA plus platinum-based chemotherapy.
Bambusa Therapeutics reports first patient dosed in proof-of-concept COPD trial
Kelun-Biotech lung cancer drug granted Breakthrough Therapy Designation in China
INOVIO's INO-3107 Biologics License Application accepted by US FDA
Sanofi and Regeneron's Dupixent gains Japan approval for paediatric asthma patients aged 6 to 11
Aqualung Therapeutics' Phase 2a lung fibrosis study approved by US FDA
Faron launches BLAZE trial with Institute of Cancer Research to address immunotherapy resistance
GSK agrees US pricing framework to expand access to respiratory medicines
Century Health partnerss with Tessel Biosciences to advance early drug development in COPD
Sanofi's efdoralprin alfa receives EU orphan designation for AATD-related emphysema